Summit Therapeutics (NASDAQ:SMMT) reported quarterly earnings results on February 23, 2026 that fell short of analyst expectations. The Healthcare company reported earnings per…
Summit Therapeutics (NASDAQ:SMMT) reported quarterly earnings results on February 23, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.14, missing the consensus estimate of $-0.10 by $0.04 per share. Revenue came in at , missing the estimate of $56.8M.
Summit Therapeutics's stock moved following the earnings release. The stock currently trades at $16.41 with a market capitalization of $13.4B.
Current market data
NASDAQ · SMMT
$17.40
Down: -$0.06 · -0.33%
Live quote updated
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Keep reading
analyst ·
analyst ·
sec_filing ·
price ·
